Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Buy" by Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have earned a consensus recommendation of "Buy" from the seven research firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.33.

Several analysts have recently commented on the company. D. Boral Capital restated a "buy" rating and set a $9.00 target price on shares of Context Therapeutics in a report on Wednesday, January 15th. Citizens Jmp upgraded shares of Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. Finally, JMP Securities initiated coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 price objective for the company.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX traded up $0.08 during mid-day trading on Thursday, reaching $0.89. The company had a trading volume of 77,171 shares, compared to its average volume of 390,187. The stock has a market capitalization of $66.57 million, a PE ratio of -0.98 and a beta of 2.06. Context Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.75. The stock's 50 day moving average is $0.96 and its 200-day moving average is $1.62.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in shares of Context Therapeutics in the 4th quarter valued at $29,000. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics during the fourth quarter worth about $31,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Context Therapeutics in the third quarter worth about $89,000. Shay Capital LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $52,000. Finally, Clear Harbor Asset Management LLC grew its holdings in Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after buying an additional 21,804 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.